UB Paderborn / Katalog / Suche / in CDI

A Causal Role for Endothelin-1 in the Pathogenesis of Osteoblastic Bone Metastases

Proceedings of the National Academy of Sciences - PNAS, 2003-09, Vol.100 (19), p.10954-10959

2003

Link zum Volltext

Verfügbarkeit prüfen

ABT-627, an endothelin ETA receptor-selective antagonist, attenuates tactile allodynia in a diabetic rat model of neuropathic pain

European journal of pharmacology, , Vol.388 (1), p.29-35

Link zum Volltext

Verfügbarkeit prüfen

The Efficacy of Terazosin, Finasteride, or Both in Benign Prostatic Hyperplasia

The New England journal of medicine, 1996-08, Vol.335 (8), p.533-540

1996

Link zum Volltext

Verfügbarkeit prüfen

Single-Dose Pharmacokinetics of Atrasentan, an Endothelin-A Receptor Antagonist

Journal of clinical pharmacology, 2001-04, Vol.41 (4), p.397-403

2001

Link zum Volltext

Verfügbarkeit prüfen

Atrasentan, an Endothelin-Receptor Antagonist for Refractory Adenocarcinomas: Safety and Pharmacokinetics

Journal of clinical oncology, 2002-04, Vol.20 (8), p.2171-2180

2002

Link zum Volltext

Verfügbarkeit prüfen

Meta-analysis of randomized trials of terazosin in the treatment of benign prostatic hyperplasia

Urology (Ridgewood, N.J.), 2001-11, Vol.58 (5), p.717-722

2001

Link zum Volltext

Verfügbarkeit prüfen

Effects of terazosin therapy on blood pressure in men with benign prostatic hyperplasia concurrently treated with other antihypertensive medications

Urology (Ridgewood, N.J.), 1999-07, Vol.54 (1), p.81-85

1999

Link zum Volltext

Verfügbarkeit prüfen

The hytrin community assessment trial study: A one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia

Urology (Ridgewood, N.J.), 1996-02, Vol.47 (2), p.159-168

1996

Link zum Volltext

Verfügbarkeit prüfen

Evidence for Vasoconstriction Mediated by the Endothelin-B Receptor in Domestic Swine

Journal of cardiovascular pharmacology, 2000-06, Vol.35 (6), p.838-844

2000

Link zum Volltext

Verfügbarkeit prüfen

The cost-effectiveness of terazosin and placebo in the treatment of moderate to severe benign prostatic hyperplasia

Urology (Ridgewood, N.J.), 1996-02, Vol.47 (2), p.169-178

1996

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics and pharmacodynamic effects of ABT‐627, an oral ETA selective endothelin antagonist, in humans

British journal of clinical pharmacology, 2000-06, Vol.49 (6), p.562-573

2000

Link zum Volltext

Verfügbarkeit prüfen

Selective ETA receptor antagonism reduces neointimal hyperplasia in a porcine coronary stent model

Circulation (New York, N.Y.), 1998-06, Vol.97 (25), p.2551-2556

1998

Link zum Volltext

Verfügbarkeit prüfen

Proapoptotic anti-inflammatory drugs

Urology (Ridgewood, N.J.), 2001-04, Vol.57 (4), p.73-76

2001

Link zum Volltext

Verfügbarkeit prüfen

Selective ETA receptor antagonism with ABT-627 attenuates all renal effects of endothelin in humans

Journal of the American Society of Nephrology, 2000-08, Vol.11 (8), p.1498-1504

2000

Link zum Volltext

Verfügbarkeit prüfen

Effect of Endothelin-A Receptor Blockade With Atrasentan on Tumor Progression in Men With Hormone-Refractory Prostate Cancer: A Randomized, Phase II, Placebo-Controlled Trial

Journal of clinical oncology, 2003-02, Vol.21 (4), p.679-689

2003

Link zum Volltext

Verfügbarkeit prüfen

Other novel agents: Rationale and current status as chemopreventive agents

Urology (Ridgewood, N.J.), 2001-04, Vol.57 (4), p.86-89

2001

Link zum Volltext

Verfügbarkeit prüfen

FRI0176 ABT-122, A Novel Dual Variable Domain (DVD)-IG™, Targeting TNF and IL-17, Inhibits Peripheral Blood Mononuclear Cell Production of GM-CSF and Decreases Lymphocyte Expression of CXCR4 in Healthy Subjects

Annals of the rheumatic diseases, 2015-06, Vol.74 (Suppl 2), p.487-487

2015

Link zum Volltext

Verfügbarkeit prüfen

Differential labeling of rat hepatic Golgi and serum very low density lipoprotein apoprotein B variants

Journal of lipid research, 1987-02, Vol.28 (2), p.207-215

1987

Link zum Volltext

Verfügbarkeit prüfen

FRI0188 Safety, Tolerability, and Pharmacodynamics of ABT-122, A Dual TNF- and IL-17–Targeted Dual Variable Domain (DVD)-IG™ in Patients with Rheumatoid Arthritis

Annals of the rheumatic diseases, 2016-06, Vol.75 (Suppl 2), p.498-498

2016

Link zum Volltext

Verfügbarkeit prüfen

FRI0156 Pharmacokinetics of ABT-122, A Dual TNF- and IL-17A-Targeted DVD-IG™, After Single Dosing in Healthy Volunteers and Multiple Dosing in Subjects with Rheumatoid Arthritis

Annals of the rheumatic diseases, 2015-06, Vol.74 (Suppl 2), p.479-479

2015

Link zum Volltext

Verfügbarkeit prüfen

ABT-627, an endothelin ET A receptor-selective antagonist, attenuates tactile allodynia in a diabetic rat model of neuropathic pain

European journal of pharmacology, 2000-01, Vol.388 (1), p.29-35

2000

Link zum Volltext

Verfügbarkeit prüfen

FRI0164 Safety, Tolerability, And Functional Activity of ABT-122, A Dual TNF- and IL-17A–Targeted DVD-IG™, Following Single-Dose Administration in Healthy Subjects

Annals of the rheumatic diseases, 2015-06, Vol.74 (Suppl 2), p.482-483

2015

Link zum Volltext

Verfügbarkeit prüfen

Niacin extended-release/simvastatin combination therapy produces larger favorable changes in high-density lipoprotein particles than atorvastatin monotherapy

Vascular health and risk management, 2012-01, Vol.8 (default), p.39-44

2012

Link zum Volltext

Verfügbarkeit prüfen

Multiple-Dose Pharmacokinetics of Atrasentan, an Endothelin-A Receptor Antagonist

Clinical drug investigation, 2001, Vol.21 (2), p.129-136

2001

Link zum Volltext

Verfügbarkeit prüfen

The apoprotein B-independent hepatic uptake of chylomicron remnants

Biochemical journal, 1982-05, Vol.204 (2), p.609-612

1982

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

A Causal Role for Endothelin-1 in the Pathogenesis of Osteoblastic Bone Metastases

ABT-627, an endothelin ETA receptor-selective antagonist, attenuates tactile allodynia in a diabetic rat model of neuropathic pain

The Efficacy of Terazosin, Finasteride, or Both in Benign Prostatic Hyperplasia

Single-Dose Pharmacokinetics of Atrasentan, an Endothelin-A Receptor Antagonist

Atrasentan, an Endothelin-Receptor Antagonist for Refractory Adenocarcinomas: Safety and Pharmacokinetics

Meta-analysis of randomized trials of terazosin in the treatment of benign prostatic hyperplasia

Effects of terazosin therapy on blood pressure in men with benign prostatic hyperplasia concurrently treated with other antihypertensive medications

The hytrin community assessment trial study: A one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia

Evidence for Vasoconstriction Mediated by the Endothelin-B Receptor in Domestic Swine

The cost-effectiveness of terazosin and placebo in the treatment of moderate to severe benign prostatic hyperplasia

Pharmacokinetics and pharmacodynamic effects of ABT‐627, an oral ETA selective endothelin antagonist, in humans

Selective ETA receptor antagonism reduces neointimal hyperplasia in a porcine coronary stent model

Proapoptotic anti-inflammatory drugs

Selective ETA receptor antagonism with ABT-627 attenuates all renal effects of endothelin in humans

Effect of Endothelin-A Receptor Blockade With Atrasentan on Tumor Progression in Men With Hormone-Refractory Prostate Cancer: A Randomized, Phase II, Placebo-Controlled Trial

Other novel agents: Rationale and current status as chemopreventive agents

FRI0176 ABT-122, A Novel Dual Variable Domain (DVD)-IG™, Targeting TNF and IL-17, Inhibits Peripheral Blood Mononuclear Cell Production of GM-CSF and Decreases Lymphocyte Expression of CXCR4 in Healthy Subjects

Differential labeling of rat hepatic Golgi and serum very low density lipoprotein apoprotein B variants

FRI0188 Safety, Tolerability, and Pharmacodynamics of ABT-122, A Dual TNF- and IL-17–Targeted Dual Variable Domain (DVD)-IG™ in Patients with Rheumatoid Arthritis

FRI0156 Pharmacokinetics of ABT-122, A Dual TNF- and IL-17A-Targeted DVD-IG™, After Single Dosing in Healthy Volunteers and Multiple Dosing in Subjects with Rheumatoid Arthritis

ABT-627, an endothelin ET A receptor-selective antagonist, attenuates tactile allodynia in a diabetic rat model of neuropathic pain

FRI0164 Safety, Tolerability, And Functional Activity of ABT-122, A Dual TNF- and IL-17A–Targeted DVD-IG™, Following Single-Dose Administration in Healthy Subjects

Niacin extended-release/simvastatin combination therapy produces larger favorable changes in high-density lipoprotein particles than atorvastatin monotherapy

Multiple-Dose Pharmacokinetics of Atrasentan, an Endothelin-A Receptor Antagonist

The apoprotein B-independent hepatic uptake of chylomicron remnants

Suchergebnisse filtern